Femara Reduces Breast Cancer Recurrence Risk

Benefit Extends Past Five Years of Tamoxifen Therapy
Women who have taken Tamoxifen as follow-up therapy after treatment for estrogen-receptor positive breast cancer can protect themselves against recurrence by taking Femara (letrozole), an aromatase inhibitor. A new study done by Dr. Paul Goss of Massachusetts General Hospital, was published in the Journal of Clinical Oncology, and shows the benefit of Femara for postmenopausal women. Femara works by blocking aromatase, preventing estrogen production and creating lower estrogen levels. Learn more about Femara.

• Hormone Therapy Drugs:
• Femara (letrozole)
• Aromasin (exemestane)
• Tamoxifen